CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2017—Trovagene has entered into a long-term supply and distribution agreement with Boreal Genomics in which they will merge their respective technologies to co-develop urine and blood ctDNA assay kits. The companies intend to address an unmet need in the liquid biopsy testing market by providing a simple, routine, and low-cost urine and blood ctDNA assay for next-generation sequencing platforms run by laboratories of research institutions, cancer centers, and service facilities around the world. Trovagene and Boreal have contributed proprietary technology and methods to enhance ctDNA detection capabilities from urine and blood to develop a series of cancer-specific multigene panels planned for launch this year.
The companies intend to develop additional panels throughout the partnership, and Trovagene plans to distribute the assay kits worldwide for use on the Boreal OnTarget system in blood and exclusively in urine. Trovagene’s initial research-use-only proprietary kits will include a urine collection kit, a urine extraction kit, and a mutation enrichment kit, along with the OnTarget system.
Trovagene, 858-952-7570
Boreal Genomics, 604-822-8268